JP2017516860A - Ａｒｆ６阻害剤並びにそれらの合成方法及び使用 - Google Patents

Ａｒｆ６阻害剤並びにそれらの合成方法及び使用 Download PDF

Info

Publication number
JP2017516860A
JP2017516860A JP2017515005A JP2017515005A JP2017516860A JP 2017516860 A JP2017516860 A JP 2017516860A JP 2017515005 A JP2017515005 A JP 2017515005A JP 2017515005 A JP2017515005 A JP 2017515005A JP 2017516860 A JP2017516860 A JP 2017516860A
Authority
JP
Japan
Prior art keywords
compound
arf6
patient
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516860A5 (enExample
Inventor
オスタニン，キリル
シェンデロビッチ，マーク
バッジ，アショク
エル． シオフィ，クリストファー
エル． シオフィ，クリストファー
モス，ニール
ヴァンカヤラパティ，ハリプラサド
リー，ディーン
Original Assignee
ナビゲン，インコーポレーテッド
ザ ユニバーシティー オブ ユタ リサーチ ファンデーション
ザ ユニバーシティー オブ ユタ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナビゲン，インコーポレーテッド, ザ ユニバーシティー オブ ユタ リサーチ ファンデーション, ザ ユニバーシティー オブ ユタ リサーチ ファンデーション filed Critical ナビゲン，インコーポレーテッド
Publication of JP2017516860A publication Critical patent/JP2017516860A/ja
Publication of JP2017516860A5 publication Critical patent/JP2017516860A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017515005A 2014-05-27 2015-05-27 Ａｒｆ６阻害剤並びにそれらの合成方法及び使用 Pending JP2017516860A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462003355P 2014-05-27 2014-05-27
US62/003,355 2014-05-27
PCT/US2015/032720 WO2015183989A1 (en) 2014-05-27 2015-05-27 Arf6 inhibitors and methods of synthesis and use thereof

Publications (2)

Publication Number Publication Date
JP2017516860A true JP2017516860A (ja) 2017-06-22
JP2017516860A5 JP2017516860A5 (enExample) 2018-07-05

Family

ID=54699729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515005A Pending JP2017516860A (ja) 2014-05-27 2015-05-27 Ａｒｆ６阻害剤並びにそれらの合成方法及び使用

Country Status (4)

Country Link
US (1) US10849901B2 (enExample)
EP (1) EP3148986A4 (enExample)
JP (1) JP2017516860A (enExample)
WO (1) WO2015183989A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2018222473A1 (en) * 2017-06-01 2018-12-06 Albert Einstein College Of Medicine, Inc. Bax activators and uses thereof in cancer therapy
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물
EP3672597A4 (en) * 2017-08-21 2021-09-22 Navigen, Inc. ARF6 INHIBITORS AND RELATED PROCEDURES
US10738056B2 (en) 2017-09-15 2020-08-11 Aduro Biotech Inc. Pyrazolopyrimidinone compounds and uses thereof
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CN117396461A (zh) * 2021-01-29 2024-01-12 美利坚合众国,由健康及人类服务部部长代表 用于靶向hrpn13的新型分子支架
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
DE102022115364A1 (de) 2022-06-21 2023-12-21 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, Körperschaft des öffentlichen Rechts FATP2 in T-Zellen als Zielmolekül zur Behandlung von Autoimmunerkrankungen
GB202319181D0 (en) * 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518178A (ja) * 2008-04-16 2011-06-23 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7555571B1 (en) * 2001-01-05 2009-06-30 Palm, Inc. Activation of mobile computing device on a cellular network
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
CA2737045C (en) * 2008-11-20 2017-11-14 Bruce Kabakoff Therapeutic protein formulations
US20120149710A1 (en) * 2009-08-24 2012-06-14 The Regents Of The University Of California Sortase a inhibitors
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
WO2012065139A2 (en) * 2010-11-11 2012-05-18 Board Of Regents, The University Of Texas System Entpd5 inhibitors
WO2012149157A2 (en) 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
CN106458904B (zh) 2014-06-10 2021-12-03 宇部兴产株式会社 N-取代磺酰胺化合物及其制造方法
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
WO2019113173A1 (en) 2017-12-06 2019-06-13 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518178A (ja) * 2008-04-16 2011-06-23 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 病的血管形成および脈管透過性の処置用の組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOSHIMOTO, A. ET AL., PLOS ONE, vol. 6, JPN6019022772, 2011, pages 23359, ISSN: 0004351326 *
JONES, C.A. ET AL., NAT CELL BIOL, vol. 11, JPN6019022771, 2009, pages 1325 - 31, ISSN: 0004351325 *

Also Published As

Publication number Publication date
EP3148986A1 (en) 2017-04-05
US20170189405A1 (en) 2017-07-06
US10849901B2 (en) 2020-12-01
EP3148986A4 (en) 2018-01-10
WO2015183989A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
US10849901B2 (en) Arf6 inhibitors and methods of synthesis and use thereof
IL284407B2 (en) Opioid receptor ligands and methods for their use and preparation
EP2271341B1 (en) Specific inhibitors for vascular endothelial growth factor receptors
JP6610562B2 (ja) ジヒドロインドリジノン誘導体
US20110086868A1 (en) Specific inhibitors for vascular endothelial growth factor receptors
JP2022141695A (ja) Ｒｈｏキナーゼ阻害剤ＢＡ‐１０４９（Ｒ）及びその活性代謝物
BR112016003247B1 (pt) Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
EP2985283A1 (en) Anti-angiogenesis compound, intermediate and use thereof
RU2650682C2 (ru) Пирролзамещенное производное индолона, способ его получения, включающая его композиция и применение
CN110678182A (zh) 含有能够穿透血脑屏障的化合物作为预防或治疗脑癌的有效成分的药物组合物
JP2022537876A (ja) カゼインキナーゼ１ε阻害剤、医薬組成物及びその使用
BRPI0613644A2 (pt) moduladores de tieno pirimidina e tieno pirimidina cinase
KR101158568B1 (ko) 신경발생을 자극 및 신경 퇴화를 억제하는 방법 및 조성물
WO2026012523A2 (zh) 钠通道调节剂
US20230144901A1 (en) Sortilin antagonists for use in the treatment of diabetic retinopathy
CN108658976B (zh) 一类新型吡唑并[4,3-c]吡啶-4(5)-酮布鲁顿激酶抑制剂
JP2021506975A (ja) 線維症を処置するための化合物および組成物
CN105985354B (zh) 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
KR102919291B1 (ko) 신규 셀레노펜 유도체
JP2023507188A (ja) 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物
RU2810065C1 (ru) ГЕТЕРОЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА КАЗЕИНКИНАЗЫ 1δ И/ИЛИ АКТИВИН-РЕЦЕПТОР-ПОДОБНОЙ КИНАЗЫ 5
JP2020528415A (ja) Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤
WO2023093787A1 (zh) 苯并二氮杂䓬类化合物及其作为Rho激酶抑制剂的应用
TW202321248A (zh) 酪胺酸激酶抑制劑
HK1236193B (en) Dihydroindolizinone derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200929